Abstract
A review of the risks and benefits of intravenous iron medicines undertaken by the European Medicines Agency Committee for Medicinal Products for Human Use will have a significant impact on home haemodialysis and non-dialysis patients across the UK. Karen Jenkins outlines the main recommendations and implications for renal practice
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
